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The International Registry of Lung Metastases waslaunched in 1990 to gather a large set of data to perform
a meta-analysis of the experience accumulated by the major
European and American centers of thoracic surgery over a
period of 50 years. We sought to evaluate the survival after
metastasectomy according to the primary tumor, to define the
prognostic factors by multivariate analysis, and to propose a
new system of classification based on long-term survival.
A comprehensive database was designed to provide a
simple and flexible instrument for the registry. This included
a single record form for each patient, which is divided into
four different sections: patient’s identification, features of the
primary neoplasm, description of every metastasectomy per-
formed, and updated follow-up.
We made an important distinction between planned
sequential surgery and repeat metastasectomy for further
recurrence. Patients who underwent planned sequential or
staged thoracotomies were considered as one single metasta-
sectomy and not as redo surgery.
Between 1991 and 1995, a total of 5290 patients were
enrolled, from 18 centers and 9 countries, including the
consecutive series of all cases operated by each center within
a given period of time. Memorial Sloan Kettering provided
the largest series, with 1075 patients treated from 1945 to
1995. Adequate information was available for most of these
patients. Only 84 cases (1.6%) were excluded because of an
incomplete dataset, thus leaving 5206 patients fully evalu-
able. The analysis was conducted by an independent agency,
the Institute of Drug Development in Brussels.
The article published as a result of this work is still
widely cited,1 and a number of other analyses have been
performed on subsets of patients. The experience is illustrated
in the Figure 1 We have applied our classification to the
different cancer types. In all cancer types, it brings about a
separation of survival trajectories, more widely dispersed in
some than in others.
It should be noted that the classification incorporates
elements identifiable before surgery (interval since the pri-
mary resection and the metastasis count) and resectability,
which is typically an operative finding. The “disease-free
interval” (DFI), defined from the data as the interval between
the primary cancer resection and the metastasectomy, is of
course an indicator of tumor doubling time while the number
of metastases is some measure of aggressiveness of the
cancer. It is noteworthy that for most cancer types, those who
have unfavorable characteristics have poor survival rates as
early as 1 to 2 years. In a recent Memorial Sloan Kettering
Cancer Center publication on colorectal metastasectomy, the
authors point out that, as a group, patients with multiple
metastases and short-time intervals are unlikely to survive for
a long period and that we are beginning to define patients who
should not be offered metastasectomy.2 Perhaps, we are
beginning to be more confident of the limits on which patients
should be offered metastasectomy.
Conversely, that patients with all three characteristics
favorable survive longer, leaves the question of whether it is
the selection for surgery, rather than the effect of surgery that
is important in survival, a possibility mooted by Aberg.3
It is also notable that the dispersion of survival by our
classification is least with breast and melanoma. Breast can-
cer regarded as being a systemic disease from when first
detected. The survival curve may support that the features
related to lung metastases are less indicative of survival than
in other diseases.
Finally, having done the difficult work on data collec-
tion for the registry, we would support the plea for better
reporting of clinical data.4
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FIGURE 1. The actuarial survival after me-
tastasectomy is depicted for patients with
various tumor types further categorized into
four groups according to respectability, soli-
tary, or multiple, the interval between pri-
mary resection and metastasectomy, and a
combination of factors known in our work
and in others to: (1) resectable, solitary, and
DFI 36 months; (2) resectable, solitary, or
DFI 36 months; (3) resectable, multiple
metastases, and DFI 36 months; and (4)
unresectable. This classification may be use-
ful in the future to stratify patients into ran-
domized trials to test new systemic treat-
ments and to further define the role of
surgery in the treatment of pulmonary me-
tastases. a, all tumor sites; b, osteosarcoma;
c, soft tissue sarcomas; d, colon cancer; e,
breast cancer; and f, melanoma. DFI, disease-
free interval.
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